TapewireFind a company

person · Reporting owner

Haas Jason

Disclosed activity across 3 companies

Tapewire entity
23537
SEC CIK
0001883821

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
LIGAND PHARMACEUTICALS INCLGND · Entity 3825DirectorAugust 12, 2026August 14, 2026
Odyssey Therapeutics, Inc.ODTX · Entity 4850Chief Financial OfficerMay 08, 2026May 12, 2026
Syros Pharmaceuticals, Inc.SYRS · Entity 85437Chief Financial OfficerNovember 18, 2024November 20, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

LIGAND PHARMACEUTICALS INC

Report date August 12, 2026 · Filed August 14, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect3,981 Ending reported balance After 2026-08-12 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-08-12 · Exercise / conversion · Acquired 6,138 · Balance 11,119

Row 2 · 2026-08-12 · Sale · Disposed 7,138 · Balance 3,981

F1: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $292.5000 to $292.8550. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.56 · Expires 2032-06-29Direct0 Reported balance After 2026-08-12 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-08-12 · Exercise / conversion · Disposed 6,138 · Balance 0

F2: This Option was previously reported as a Grant of 5,907 shares on June 29, 2022, at an exercise price of $88.48 per share, which becomes exercisable in three successive annual installments upon completion of each calendar year of service beginning on the grant date, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $292.5000 to $292.8550. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: This Option was previously reported as a Grant of 5,907 shares on June 29, 2022, at an exercise price of $88.48 per share, which becomes exercisable in three successive annual installments upon completion of each calendar year of service beginning on the grant date, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.

Odyssey Therapeutics, Inc.

Report date May 08, 2026 · Filed May 12, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect62,908 Reported balance After 2026-05-08 transaction · row 1
1 source row

Row 1 · 2026-05-08 · Purchase · Acquired 1,000 · Balance 62,908

Syros Pharmaceuticals, Inc.

Report date November 18, 2024 · Filed November 20, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2024-11-18 transaction · row 1
1 source row

Row 1 · 2024-11-18 · Sale · Disposed 137,803 · Balance 0

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.19 to $0.2295, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.19 to $0.2295, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
August 12, 2026 Filed Aug 14, 2026 21:04 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 6,138 $0.00 Strike: $51.56 $0.00
Disclosure

SEC source: 0002001011-26-000114 · edgardoc.xml · derivative · entry 3

Haas Jason · CIK 0001883821 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,138 shares

Expires 2032-06-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This Option was previously reported as a Grant of 5,907 shares on June 29, 2022, at an exercise price of $88.48 per share, which becomes exercisable in three successive annual installments upon completion of each calendar year of service beginning on the grant date, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.

Read SEC document
August 12, 2026 Filed Aug 14, 2026 21:04 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 SaleCommon Stock 7,138 $292.81 $2,090,062.08
Disclosure

SEC source: 0002001011-26-000114 · edgardoc.xml · nonDerivative · entry 2

Haas Jason · CIK 0001883821 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,981

F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $292.5000 to $292.8550. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 12, 2026 Filed Aug 14, 2026 21:04 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 Exercise / conversionCommon Stock 6,138 $51.56 $316,475.28
Disclosure

SEC source: 0002001011-26-000114 · edgardoc.xml · nonDerivative · entry 1

Haas Jason · CIK 0001883821 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,119

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 12, 2026 Filed Jun 16, 2026 01:06 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 1,000 $0.00 Strike: $51.56 $0.00
Disclosure

SEC source: 0002001011-26-000104 · edgardoc.xml · derivative · entry 6

Haas Jason · CIK 0001883821 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,138

Underlying: Common Stock · 1,000 shares

Expires 2032-06-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This Option was previously reported as a Grant of 5,907 shares on June 29, 2022, at an exercise price of $88.48 per share, which becomes exercisable in three successive annual installments upon completion of each calendar year of service beginning on the grant date, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.

Read SEC document
June 12, 2026 Filed Jun 16, 2026 01:06 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 3,000 $0.00 Strike: $51.56 $0.00
Disclosure

SEC source: 0002001011-26-000104 · edgardoc.xml · derivative · entry 5

Haas Jason · CIK 0001883821 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,138

Underlying: Common Stock · 3,000 shares

Expires 2032-06-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This Option was previously reported as a Grant of 5,907 shares on June 29, 2022, at an exercise price of $88.48 per share, which becomes exercisable in three successive annual installments upon completion of each calendar year of service beginning on the grant date, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.

Read SEC document
June 12, 2026 Filed Jun 16, 2026 01:06 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 SaleCommon Stock 3,461 $256.08 $886,286.30
Disclosure

SEC source: 0002001011-26-000104 · edgardoc.xml · nonDerivative · entry 4

Haas Jason · CIK 0001883821 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,981

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $256.0000 to $256.5100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
June 12, 2026 Filed Jun 16, 2026 01:06 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 SaleCommon Stock 3,000 $255.01 $765,033.90
Disclosure

SEC source: 0002001011-26-000104 · edgardoc.xml · nonDerivative · entry 3

Haas Jason · CIK 0001883821 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,442

F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $255.0000 to $255.2900. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
June 12, 2026 Filed Jun 16, 2026 01:06 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 Exercise / conversionCommon Stock 1,000 $51.56 $51,560.00
Disclosure

SEC source: 0002001011-26-000104 · edgardoc.xml · nonDerivative · entry 2

Haas Jason · CIK 0001883821 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,442

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 12, 2026 Filed Jun 16, 2026 01:06 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 Exercise / conversionCommon Stock 3,000 $51.56 $154,680.00
Disclosure

SEC source: 0002001011-26-000104 · edgardoc.xml · nonDerivative · entry 1

Haas Jason · CIK 0001883821 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,442

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 05, 2026 Filed Jun 9, 2026 23:35 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 GrantNon-Qualified Stock Option (right to buy) · Derivative 2,938 $0.00 Strike: $237.00 $0.00
Disclosure

SEC source: 0002001011-26-000097 · edgardoc.xml · derivative · entry 2

Haas Jason · CIK 0001883821 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,938

Underlying: Common Stock · 2,938 shares

Expires 2036-06-05

F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

Read SEC document
June 05, 2026 Filed Jun 9, 2026 23:35 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 GrantCommon Stock 836 $0.00 $0.00
Disclosure

SEC source: 0002001011-26-000097 · edgardoc.xml · nonDerivative · entry 1

Haas Jason · CIK 0001883821 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,442

F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

Read SEC document
May 08, 2026 Filed May 12, 2026 00:32 UTC Odyssey Therapeutics, Inc. ODTX · Entity 4850 PurchaseCommon Stock 1,000 $20.00 $20,000.00
Disclosure

SEC source: 0001193125-26-217600 · ownership.xml · nonDerivative · entry 1

Haas Jason · CIK 0001883821 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,908

Read SEC document
June 06, 2025 Filed Jun 10, 2025 23:20 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 GrantNon-Qualified Stock Option (right to buy) · Derivative 5,783 $0.00 Strike: $105.99 $0.00
Disclosure

SEC source: 0002001011-25-000040 · edgardoc.xml · derivative · entry 2

Haas Jason · CIK 0001883821 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,783

Underlying: Common Stock · 5,783 shares

Expires 2035-06-06

F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

Read SEC document
June 06, 2025 Filed Jun 10, 2025 23:20 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 GrantCommon Stock 1,209 $0.00 $0.00
Disclosure

SEC source: 0002001011-25-000040 · edgardoc.xml · nonDerivative · entry 1

Haas Jason · CIK 0001883821 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,606

F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

Read SEC document
November 18, 2024 Filed Nov 20, 2024 17:00 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 SaleCommon Stock 137,803 $0.21 $28,979.97
Disclosure

SEC source: 0000950170-24-129378 · ownership.xml · nonDerivative · entry 1

Haas Jason · CIK 0001883821 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.19 to $0.2295, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Read SEC document
October 31, 2024 Filed Nov 4, 2024 17:01 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 Exercise / conversionRestricted Stock Units · Derivative 18,875 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-120869 · ownership.xml · derivative · entry 3

Haas Jason · CIK 0001883821 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 18,875 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

F4 · derivative.exercise_date: Represents a restricted stock unit award granted on October 6, 2022. These restricted stock units vested as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024.

F4 · derivative.expiration_date: Represents a restricted stock unit award granted on October 6, 2022. These restricted stock units vested as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024.

Read SEC document
October 31, 2024 Filed Nov 4, 2024 17:01 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 Tax withholdingCommon Stock 5,624 $2.09 $11,754.16
Disclosure

SEC source: 0000950170-24-120869 · ownership.xml · nonDerivative · entry 2

Haas Jason · CIK 0001883821 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 137,803

F2 · kind: Represents shares used to cover tax withholding on a restricted stock unit release.

Read SEC document
October 31, 2024 Filed Nov 4, 2024 17:01 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 Exercise / conversionCommon Stock 18,875 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-120869 · ownership.xml · nonDerivative · entry 1

Haas Jason · CIK 0001883821 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 143,427

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award.

F1 · price: Represents shares of common stock received upon vesting of a restricted stock unit award.

Read SEC document
September 12, 2024 Filed Sep 12, 2024 17:00 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 PurchaseCommon Stock 45,344 $1.68 $76,005.61
Disclosure

SEC source: 0000950170-24-105995 · ownership.xml · nonDerivative · entry 3

Haas Jason · CIK 0001883821 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 124,552

F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.62 to $1.69, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Read SEC document
September 11, 2024 Filed Sep 12, 2024 17:00 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 PurchaseCommon Stock 19,293 $1.58 $30,446.28
Disclosure

SEC source: 0000950170-24-105995 · ownership.xml · nonDerivative · entry 2

Haas Jason · CIK 0001883821 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,208

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.55 to $1.60, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Read SEC document
September 10, 2024 Filed Sep 12, 2024 17:00 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 PurchaseCommon Stock 35,363 $1.55 $54,787.90
Disclosure

SEC source: 0000950170-24-105995 · ownership.xml · nonDerivative · entry 1

Haas Jason · CIK 0001883821 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,915

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.50 to $1.57, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Read SEC document
June 14, 2024 Filed Jun 19, 2024 01:26 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 GrantNon-Qualified Stock Option (right to buy) · Derivative 5,444 $0.00 Strike: $80.06 $0.00
Disclosure

SEC source: 0002001011-24-000057 · edgardoc.xml · derivative · entry 2

Haas Jason · CIK 0001883821 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,444

Underlying: Common Stock · 5,444 shares

Expires 2034-06-14

F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 14, 2024. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

Read SEC document
June 14, 2024 Filed Jun 19, 2024 01:26 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 GrantCommon Stock 1,252 $0.00 $0.00
Disclosure

SEC source: 0002001011-24-000057 · edgardoc.xml · nonDerivative · entry 1

Haas Jason · CIK 0001883821 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,397

F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 14, 2024. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

Read SEC document
April 01, 2024 Filed Apr 2, 2024 16:54 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 Tax withholdingCommon Stock 4,732 $5.12 $24,227.84
Disclosure

SEC source: 0000950170-24-040289 · ownership.xml · nonDerivative · entry 3

Haas Jason · CIK 0001883821 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,552

F2 · kind: Represents shares used to cover tax withholding upon the release of restricted stock units.

Read SEC document
March 31, 2024 Filed Apr 2, 2024 16:54 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 Exercise / conversionRestricted Stock Units · Derivative 13,333 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-040289 · ownership.xml · derivative · entry 5

Haas Jason · CIK 0001883821 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,667

Underlying: Common Stock · 13,333 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

F5 · derivative.exercise_date: Represents a restricted stock unit award granted on February 16, 2023. These restricted stock units vest in three equal annual installments commencing on March 31, 2024.

F5 · derivative.expiration_date: Represents a restricted stock unit award granted on February 16, 2023. These restricted stock units vest in three equal annual installments commencing on March 31, 2024.

Read SEC document
March 31, 2024 Filed Apr 2, 2024 16:54 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 Exercise / conversionRestricted Stock Units · Derivative 2,000 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-040289 · ownership.xml · derivative · entry 4

Haas Jason · CIK 0001883821 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,000

Underlying: Common Stock · 2,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

F4 · derivative.exercise_date: Represents a restricted stock unit award granted on February 15, 2022. These restricted stock units vest in four equal annual installments commencing on March 31, 2023.

F4 · derivative.expiration_date: Represents a restricted stock unit award granted on February 15, 2022. These restricted stock units vest in four equal annual installments commencing on March 31, 2023.

Read SEC document
March 31, 2024 Filed Apr 2, 2024 16:54 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 Exercise / conversionCommon Stock 13,333 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-040289 · ownership.xml · nonDerivative · entry 2

Haas Jason · CIK 0001883821 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,284

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award.

F1 · price: Represents shares of common stock received upon vesting of a restricted stock unit award.

Read SEC document
March 31, 2024 Filed Apr 2, 2024 16:54 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 Exercise / conversionCommon Stock 2,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-040289 · ownership.xml · nonDerivative · entry 1

Haas Jason · CIK 0001883821 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,951

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award.

F1 · price: Represents shares of common stock received upon vesting of a restricted stock unit award.

Read SEC document
November 01, 2023 Filed Nov 2, 2023 16:53 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 Tax withholdingCommon Stock 6,301 $2.22 $13,988.22
Disclosure

SEC source: 0001209191-23-054172 · doc4.xml · nonDerivative · entry 2

Haas Jason · CIK 0001883821 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,951

F2 · kind: Represents shares used to cover tax withholding on a restricted stock unit release.

Read SEC document
October 31, 2023 Filed Nov 2, 2023 16:53 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 Exercise / conversionRestricted Stock Units · Derivative 18,875 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-054172 · doc4.xml · derivative · entry 3

Haas Jason · CIK 0001883821 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,875

Underlying: Common Stock · 18,875 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

F4 · derivative.exercise_date: Represents a restricted stock unit award granted on October 6, 2022. These restricted stock units vested as to one half (50%) of the shares on October 31, 2023, and are scheduled to vest as to one half (50%) of the shares on October 31, 2024.

F4 · derivative.expiration_date: Represents a restricted stock unit award granted on October 6, 2022. These restricted stock units vested as to one half (50%) of the shares on October 31, 2023, and are scheduled to vest as to one half (50%) of the shares on October 31, 2024.

Read SEC document
October 31, 2023 Filed Nov 2, 2023 16:53 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 Exercise / conversionCommon Stock 18,875 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-054172 · doc4.xml · nonDerivative · entry 1

Haas Jason · CIK 0001883821 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,252

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award.

F1 · price: Represents shares of common stock received upon vesting of a restricted stock unit award.

Read SEC document
June 09, 2023 Filed Jun 13, 2023 22:53 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 GrantNon-Qualified Stock Option (right to buy) · Derivative 5,461 $0.00 Strike: $73.76 $0.00
Disclosure

SEC source: 0000886163-23-000039 · edgardoc.xml · derivative · entry 2

Haas Jason · CIK 0001883821 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,461

Underlying: Common Stock · 5,461 shares

Expires 2033-06-09

F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 9, 2023. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

Read SEC document
June 09, 2023 Filed Jun 13, 2023 22:53 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 GrantCommon Stock 1,142 $0.00 $0.00
Disclosure

SEC source: 0000886163-23-000039 · edgardoc.xml · nonDerivative · entry 1

Haas Jason · CIK 0001883821 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,145

F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 9, 2023. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

Read SEC document
April 03, 2023 Filed Apr 4, 2023 18:57 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 Tax withholdingCommon Stock 623 $2.58 $1,607.34
Disclosure

SEC source: 0001209191-23-022979 · doc4.xml · nonDerivative · entry 2

Haas Jason · CIK 0001883821 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,377

F3 · kind: Represents shares used to cover tax withholding on a restricted stock unit release.

Read SEC document
March 31, 2023 Filed Apr 4, 2023 18:57 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 Exercise / conversionRestricted Stock Units · Derivative 2,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-022979 · doc4.xml · derivative · entry 3

Haas Jason · CIK 0001883821 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Common Stock · 2,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

F5 · derivative.exercise_date: Represents a restricted stock unit award granted on February 15, 2022. These restricted stock units vest in four equal annual installments commencing on March 31, 2023.

F5 · derivative.expiration_date: Represents a restricted stock unit award granted on February 15, 2022. These restricted stock units vest in four equal annual installments commencing on March 31, 2023.

F2 · balance_after: On September 16, 2022, the issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

Read SEC document
March 31, 2023 Filed Apr 4, 2023 18:57 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 Exercise / conversionCommon Stock 2,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-022979 · doc4.xml · nonDerivative · entry 1

Haas Jason · CIK 0001883821 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award.

F1 · price: Represents shares of common stock received upon vesting of a restricted stock unit award.

F2 · balance_after: On September 16, 2022, the issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

Read SEC document
February 16, 2023 Filed Feb 21, 2023 16:21 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 GrantRestricted Stock Units · Derivative 40,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-011162 · doc4.xml · derivative · entry 1

Haas Jason · CIK 0001883821 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock.

F2 · derivative.exercise_date: These RSUs will vest as to one third (1/3rd) of the shares underlying the award on March 31, 2024 and as to an additional one third (1/3rd) of such shares at the end of each successive year thereafter.

F2 · derivative.expiration_date: These RSUs will vest as to one third (1/3rd) of the shares underlying the award on March 31, 2024 and as to an additional one third (1/3rd) of such shares at the end of each successive year thereafter.

Read SEC document
October 06, 2022 Filed Oct 11, 2022 16:37 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 GrantRestricted Stock Units · Derivative 37,750 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-053316 · doc4.xml · derivative · entry 2

Haas Jason · CIK 0001883821 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,750

Underlying: Common Stock · 37,750 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock.

F3 · derivative.exercise_date: These RSUs will vest as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024.

F3 · derivative.expiration_date: These RSUs will vest as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024.

Read SEC document
October 06, 2022 Filed Oct 11, 2022 16:37 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 GrantStock Option (right to buy) · Derivative 49,750 $0.00 Strike: $6.73 $0.00
Disclosure

SEC source: 0001209191-22-053316 · doc4.xml · derivative · entry 1

Haas Jason · CIK 0001883821 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,750

Underlying: Common Stock · 49,750 shares

Expires 2032-10-05

F1 · derivative.exercise_date: This option becomes exercisable as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024.

Read SEC document
June 29, 2022 Filed Jun 30, 2022 22:32 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 GrantNon-Qualified Stock Option (right to buy) · Derivative 5,907 $0.00 Strike: $88.48 $0.00
Disclosure

SEC source: 0000886163-22-000103 · edgardoc.xml · derivative · entry 2

Haas Jason · CIK 0001883821 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,907

Underlying: Common Stock · 5,907 shares

Expires 2032-06-29

F1 · derivative.exercise_date: The option becomes exercisable in 3 successive annual installments upon completion of each calendar year of service beginning on the grant date.

Read SEC document
June 29, 2022 Filed Jun 30, 2022 22:32 UTC LIGAND PHARMACEUTICALS INC LGND · Entity 3825 GrantCommon Stock 1,750 $0.00 $0.00
Disclosure

SEC source: 0000886163-22-000103 · edgardoc.xml · nonDerivative · entry 1

Haas Jason · CIK 0001883821 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,750

Read SEC document
February 15, 2022 Filed Feb 17, 2022 16:07 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 GrantRestricted Stock Units · Derivative 80,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-010707 · doc4.xml · derivative · entry 2

Haas Jason · CIK 0001883821 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock.

F3 · derivative.exercise_date: These RSUs will vest in four equal annual installments commencing on March 31, 2023.

F3 · derivative.expiration_date: These RSUs will vest in four equal annual installments commencing on March 31, 2023.

Read SEC document
February 15, 2022 Filed Feb 17, 2022 16:07 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 GrantStock Option (right to buy) · Derivative 125,000 $0.00 Strike: $1.59 $0.00
Disclosure

SEC source: 0001209191-22-010707 · doc4.xml · derivative · entry 1

Haas Jason · CIK 0001883821 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2032-02-14

F1 · derivative.exercise_date: This option becomes exercisable as to one quarter (1/4th) of the shares on February 28, 2023, with the remainder vesting in monthly installments equal to one forty-eighth (1/48th) of the original number of shares at the end of each of the next thirty-six (36) months thereafter.

Read SEC document
October 12, 2021 Filed Oct 13, 2021 16:06 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 GrantStock Option (right to buy) · Derivative 750,000 $0.00 Strike: $4.54 $0.00
Disclosure

SEC source: 0001209191-21-060358 · doc4.xml · derivative · entry 1

Haas Jason · CIK 0001883821 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 750,000

Underlying: Common Stock · 750,000 shares

Expires 2031-10-11

F1 · derivative.exercise_date: This option becomes exercisable as to one quarter (1/4th) of the shares on October 12, 2022, with the remainder vesting in monthly installments equal to one forty-eighth (1/48th) of the original number of shares at the end of each of the next thirty-six (36) months thereafter.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.